GSK and Hengrui Pharma Forge $500 Million China Collaboration, Including PDE3/4 Inhibitors

1. GSK paid $500 million upfront for global development rights to Hengrui’s portfolio of up to 12 early-stage assets.

2. Includes a PDE3/4 inhibitor for COPD plus programs in oncology, respiratory, immunology, and inflammation.

On July 28, 2025, GSK announced a $500 million upfront agreement with China’s Jiangsu Hengrui, with a potential total value exceeding $12 billion. The portfolio spans respiratory, oncology, immunology, and inflammatory diseases, including HRS-9821, a PDE3/4 inhibitor for COPD. The joint press release emphasized the synergy between Hengrui’s R&D capabilities and GSK’s commercialization expertise. Market data from Evaluate Vantage projects China’s branded pharmaceutical market to grow more than 8% annually through 2030. The collaboration strengthens GSK’s mid-stage pipeline and deepens its access to Asia’s largest healthcare market. For Hengrui, the agreement offers significant milestone opportunities and entry into new markets. Industry analysts see this as one of the largest UK–China pharma collaborations in recent years. The deal also reflects a broader trend of cross-border R&D partnerships despite global political tensions. By securing rights to multiple promising assets, GSK positions itself for growth across both mature and emerging markets. The collaboration highlights the growing importance of cross-border pharmaceutical alliances in accelerating drug development for underserved conditions. Analysts expect that success in early trials could lead to accelerated approval pathways in multiple jurisdictions. For Hengrui, the deal could serve as a blueprint for future partnerships with Western firms seeking entry into Asian markets. GSK’s interest in Hengrui’s respiratory and oncology assets aligns with its broader strategic pivot toward specialty medicines with strong growth potential. If the partnership meets its development and regulatory goals, it could bring several first-in-class therapies to market within the decade.

Image: PD

©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.